Newer fluoroquinolones such as ciprofloxacin, pefloxacin, ofloxacin, enoxacin, and fleroxacin are potent antimicrobial agents against many gram-negative bacteria, including Pseudomonas aeruginosa species and staphylococci-sensitive or resistant to methicillin. They are almost completely absorbed when given orally, reaching therapeutic plasma and dialysate concentrations, and their long half lives permit infrequent dosing intervals.
gation in order to establish their role in clinical practice.
Despite many technological improvements, peritonitis and exit-site infections remain a major problem in CAPD. Although the incidence of these infections has declined to one episode every 12 to 18 patient months, some difficultto-treat infections usually re sult in prolonged hospitalization, catheter loss, and temporary or permanent transfer to hemodialysis all of which increase overall costs and patient morbid ity (2) (3) (4) .
In addition, therapeutic failures and relapses often result in the emergence of resistant bacteria. There fore, all will welcome and thoroughly investigate new antibiotics with specific advantages in the management of peritonitis and exit-site infections.
PHARMACOLOGY
The pharmacokinetic profile of fluoroquinolones show some interesting and important clinical properties. Because they have excellent absorption after oral a dministration, they can be administered orally. One or two hours after oral administration, the maximum serum concentrations (Cmax) are higher than the minimum inhibitory concentrations (MIC) for most sensitive pathogens (5) . Their elimination half life is 4 to 12 h, permitting treatment with one or two doses per day (5, 6) . The fluoroquinolones have a low protein binding (approximately 30%) and rapidly penetrate the extravascular space and various tissues, including the meninges, human neutrophils and t he peritoneum (7) (8) (9) (10) (11) . Because of their ability to concentrate within human leukocytes, they have a potential role in infections caused by intracellular path ogens like staphylococci, legionella, and mycobacteria.
The fluoroquinolones are metabolised to a various extent and excreted unchanged or as their metabolites (12) .
In patients with renal failure, their pharmacoki netic behavior is altered according to their degree of metabolism. Thus ofloxacin, which is excreted unchanged in the urine, has a prolonged elimination half life of 37 h (13). At the opposite end, the pharmacokinetics of pefloxacin are unchanged in patients with mild or severe renal impairment because it is metabolized in the liver (14) . The pharmacokinetics of ciprofloxacin, enoxacin, and fleroxacin are only slightly influenced by decreased renal function; their elimina tion half lives are prolonged only two to four times (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Therefore, in patients with renal failure, the dosage must be adjusted but not that of pefloxacin. For ciprofloxacin and fleroxacin, a dose reduction of 50% has been proposed in patients with a creatinine clearance lower than 20 mL/min (16, 17) .
Because many patients with end-stage renal failure undergo hemodialysis or peritoneal dialysis, it is desirable to know what influence these procedures have on the elimination of fluoroquinolones so to avoid drug accumulation or therapeutic failures. Although they have a low protein binding and low molecular weight (386 to 429), the fluoroquinolones are only moderately eliminated by hemodialysis, possibly because of their relatively high lipid solubility; thus for ciprofloxacin, pefloxacin, and ofloxacin, hemodialysis extracts less than 30% of the administered dose (14, 18, 19) .
There is limited information about the pharmacokinetics of fluoroquinolones in CAPD patients. After a single oral dose of 750 mg of ciprofloxacin, mean serum concentration in peritoneal effluent was 1.3 mg/L and the elimination half life 16.8 h (20) . An oral dose of 750 mg twice or 250 mg four times a day produces higher concentrations in serum and dialysate. An oral dose of 750 mg every 12 h gives peak serum concentrations between 2.9 and 6.4 mg/L; correspondingly, peak dialysate concentrations are 1.8 to 4.5 mg/L (21). With these doses there was no accumulation of ciprofloxacin in uremic patients possibly because of compensatory extrarenal elimination (22) . Fleming et al. , using a dose of 250 mg every 6 h for four days obtained mean peak plasma levels ranging between 1.6 mg/L, after the first dose and 3.08 mg/L after the other doses. Mean peak dialysate concentration reached the 2.17 mg/L (23). With ofloxacin, after oral administration of a loading dose of 400 mg or 300 mg followed by 200 mg daily mean peak serum concentrations were 3.46 mg/L and 2.44 mg/L, respectively (24) . Corresponding to these plasma levels, the concentrations of ofloxacin in the dialysate during the first 24 h ranged between 2.72 to 3.02 mg/L. These values are higher than those of ciprofloxacin. However, prolonged treatment with ofloxacin in the above doses might lead to toxic accumulation because of its large renal elimination and low metabolism.
Mean dialysate concentrations of fleroxacin after a single oral 400 mg dose reach 1.5 mg/L (25), but multiple dose studies are needed to define its kinetic behavior in CAPD patients.
Peritoneal fluid-to-plasma concentration ratio of the fluoroquinolones, which expresses the percentage of drug crossing the peritoneal membrane, increase with the duration of dwell time. Thus for dwell periods of 4, 6 and 8 h, the dialysate-to-plasma concentration ratios of ciprofloxacin were 57%, 64%, and 75%, respectively (20, 21) . Likewise the mean dialysate/plasma concentration ratios of fleroxacin is in creased from 52% to 71% when the dwell time is increased from 3 to 6 h (25). To achieve higher concentrations in peritoneal dialysate during the treatment of peritonitis one needs a dwell time of 6 or 8 h per exchange.
No one yet knows the influence of peritonitis on the fluoroquinolones kinetics. Fleming et al. showed that the ciprofloxacin concentration in the dialysate does not differ significantly with and without peritonitis (mean dialysate concentration 1.88 mg/L vs. 2.44 mg/L, respectively) (23) .
A significant decrease in serum and consequently dialysate concentrations of the fluoroquinolones has been observed after the concomitant administration of antacids. Antacids containing aluminum and/or magnesium hydroxide, which are commonly used in uremic patients, markedly reduce the absorption of the fluoroquinolones possibly by chelation (6). Thus, peak serum ciprofloxacin concentrations in patients taking antacids were 14 to 50% of the concentrations obtained without antacids. Similarly, the peak dialysate concentrations while the patients were on antacids were only 8 to 33% of those observed in patients not taking antacids (21, 26) . Therefore, this interaction of the newer quinolones with antacids may result in subtherapeutic concentrations in serum and dialysate d uring the treatment of peritonitis.
CAPD has only a negligible effect on the elimina tion kinetics of the fluoroquinolones. Thus, the fraction of the administered dose removed by peritoneal dialysis is only 1.6% for ciprofloxacin, 7 to 8% for fleroxacin and 2% for ofloxacin (22, 24, 25) . As a result in patients undergoing CAPD their elimination half lives is prolonged because they are in end-stage renal failure (Table 1) . Therefore, the dose adjustments proposed for patients with renal failure must be followed in CAPD patients as well.
MICROBIOLOGY
The fluoroquinolones have a remarkable bactericidal activity against gram-positive and negative organisms. The primary target of their action is the bacterial enzyme DNA-gyrase, which is involved in a number of critical DNA reactions. The fluoroquinolones bind specifically to the DNA-gyrase causing breaks in the DNA, inhibition of cell division, and the death of the cell (27) .
In contrast to the older quinolones, which were active only against some species of enterobacteriaceae, the fluoroquinolones have an extended spectrum of activity. They are active against most enterobacteriaceae such as E. coli, Proteus species, Klebsiella, Enterobacter, Citrabacter, Serratia, Salmonella, Shigella, and also against Hemaphilus influenzae, Acinetabacter, and Pseudamanas aeruginosa. Their activity against Pseudomanas varies considerably depending on the specific drug. In addition, some clinically im portant gram-positive organisms such as Staphylococcus aureus and epidermidis sensitive or resistant to methicillin and intracellular microbes such as mycobacterium, mycoplasma, and Legianella pneumophila are sensitive to the fluoroquinolones. However, they have poor activity against anaerobic bacteria and intermediate or little activity against Streptacocci (28) . It is of special interest that the antimicrobial action of the fluoroquinolones is also directed to the b-lactam or aminoglycoside-resistant strains (29, 30) .
The minimal inhibitory concentrations of these compounds are low (50% MIC5o or 90% MIC9o) for the sensitive pathogens. Most isolates are inhibited by 0.002 to 2 mg/L, a concentration that is achieved eas ily with the usual therapeutic doses (31) ( Table  2) . With respect to antimicrobial activity there are both similarities and differences between the fluoroquinolones. For most of gram-negative bacteria they have almost similar MIC5o and MIC9o, from 0.008 to 0.5 mg/L and 0.08 to 2 mg/L, respectively (39) . Pseudomonas aeruginasa is more resistant to them than are other gram-negative organisms. Of this group, cipro floxacin is the most active against pseudomonas; it has an MIC5o 0.12 to 0.20 mg/L and MIC9o 0.5 to 0.78 mg/L (33, 34) whereas enoxacin, ofloxacin, fleroxacin, and pefloxacin have higher MICs (31, 38, 39) .
Comparative in vitro studies show that the fluoroquinolones have much lower MICs for Staphylococcus aureus and Staphylacaccus epidermidis than do the cephalosporins, cloxacillin, gentamicin, and vancomycin (29, 33, 35) . Furthermore, when ciprofloxacin was compared in vitro with vancomycin against blood isolates of Staphylacaccus epidermidis, the former had (40) . Nevertheless, the clinical efficacy of the antimicrobial compounds do not depend merely on MIC or other antimicrobial characteristics; of equal importance is whether the drug reaches high enough concentrations in the infection site. Although when given orally, the fluoroquinolones do not achieve high levels in serum and peritoneal dialysis fluid, the plasma and dialysate levels are fourfold or more higher than the previously mentioned MICs for most sensitive gram-positive and -negative pathogens.
Since the antibiotics act in the dialysate during the treatment of CAPD peritonitis, we need reliable information about the effect of the dialysate on the fluoroquinolones' antimicrobial activity. Previous studies demonstrated that some antibiotics such as cephalosporins or aminoglycosides lose their activity in dialysis fluid because of its low pH and the high osmolality (41, 42) . In addition, Shalit et al. (42) reported that the dialysis effluent lowered the activity of aminoglycosides probably because these agents are sensitive to pH changes, divalent cation levels, oxidation-reduction potential, and host-derived factors in the dialysate (43, 49) .
In this regard, the bactericidal activity of ciprofloxacin is affected only slightly by low dialysate pH, while a peritoneal effluent that has a physiological pH and osmolality shows a moderate increase in bactericidal activity against Pseudamonas aeruginosa, E. cali., and staphylococcus species (44) . Furthermore, Guay et al. reported that the activity of ciprofloxacin against coagulase-positive staphylococci was not reduced by the peritoneal effluent. Against coagulasenegative strains, the effluent had a slight inhibitory effect although the MICs still remained within the clinically achievable levels (MIC &le; 1 mg/L) (45) . Ciprofloxacin also shows high bactericidal activity in peritoneal effluent against Pseudamanas aeruginosa, measured by the time kill curve technique-99.9% of strains were killed at 1 h. These results are similar to those obtained with aminoglycosides (42) .
Most staphylococci grow as microcolonies on implanted catheters and produce a biofilm (extracellular slime substance) which protects the organisms from the various defence mechanisms and from the action of antibiotics action (46, 47) . Also, evidence suggests that these Staphylacoccus species and many other organisms such as Streptococci or Pseudomanas, which are able t o produce slime, are more resistant to the inhibitory effects of various antibiotics (48, 49) . Because adherence to catheters probably contributes to the pathogenesis and relapsing course of staphylococcal peritonitis, we were anxious to examine the action of fluoroquinolones on slime production strains. In vitro tests of ciprofloxacin, ofloxacin, and pefloxacin against clinically isolated coagulase-negative staphylococcus species showed only minor differences in the bactericidal effect between slime-producing and nonproducing strains. With ciprofloxacin and ofloxacin, concentrations of &le; 1 mg/L inhibited 61% of the eval uated strains and with pefloxacin, 45%. On the contrary, organisms producing slime showed resistance to gentamicin and teicoplanin with increased frequency (50) .
According to Finch et al., when exposed to subinhibitory concentrations of vancomycin, coagulasenegative staphylococci, isolated from dialysate, showed minimal alteration in adherence whereas exposure to cefuroxime and ciprofloxacin significantly reduced this adherence (51) .
If these agents could prevent bacterial adherence on peritoneal catheters and could penetrate and kill bacterial cells in biofilms, the fluoroquinolones might contribute to the prophylaxis and treatment of catheter-related infections. However, because only a few studies on this area have been performed so far, we urgently need further in vitro and in vivo confirmation (50, 52) .
CLINICAL USE
Recently, the new oral fluoroquinolones have been investigated to find out if they constitute a simpler, less toxic and more convenient treatment of CAPD peritonitis. Their pharmacologic and microbiological features enable them to be extremely useful in this patient population.
However, we have no information on the value of fluoroquinolones in peritonitis and exit-site infection in CAPD patients. The literature contains only results of a small number of clinical trials done with ciprofloxacin, ofloxacin, and pefloxacin (Table 3) . Fleming et al. treated 21 episodes of peritonitis in 16 CAPD patients with oral ciprofloxacin at a dose of 250 or 500 mg q.i.d. (52) . In 12 episodes treated for 10 days the success rate was 100%; there were no recurrences. In two other patients with slowly resolving infection, treatment was successful after 10 to 14 days. The causative organisms included gram-positive infections due to Staph. aureus and Staph. epidermidis and gram-negative enterobacteria. One patient with an acinetobacter infection responded to a five-day course. Three patients treated for five days suffered a recurrence three to seven days after ciprofloxacin was discontinued; in these cases, a further 10 days of ciprofloxacin led to resolution of the infection. In three patients, ciprofloxacin was stopped before day 5; in two, because of nonsensitive organisms and, in one, because of vomiting. Grave and Sturm treated with parenteral ciprofloxacin an episode of peritonitis due to Pseudomanas aeruginasa in a patient who earlier had not responded to i.p. gentamicin plus ticarcillin. They started treatment with ciprofloxacin, using an initial i.v. dose of 400 mg followed by i.p. administration of 50 mg q.i.d. Dialysate effluent levels varied from 1.4 to 2.2 mg/L, whereas the MIC of ciprofloxa cin for the isolated strain of Pseudamonas aeruginosa was 0.05 mg/L. After two days, the dialysate cultures became negative (53) . Another study of ofloxacin in CAPD peritonitis compared two dosage oral regimens. In the first group, 18 episodes of peritonitis in 16 CAPD patients were treated with oral ofloxacin 400 mg initially followed by 300 mg daily for 10 days. In the second group, 10 episodes in patients were treated with the same initial dose followed by 200 mg daily for seven days. In most cases the causative pathogens were Staph. aureus and Staph. epidermidis. The overall cure rate, (negative cultures 1 and 2 months after discontinuation of the antibiotics) was 83% in the first group, and 50% in the second group (54) . The peritoneal effluent cleared completely in five days. The first regimen produced a significant serum accumulation; mean serum trough levels increased from 2.28 mg/L on day 1 to 5.83 mg/L on day 10. However despite this accumulation, the only side effects were nausea and nonspecific dizziness. Pefloxacin has given similar results; 15 episodes of CAPD peritonitis were treated with an i. v. dose of 800 mg on the first day, followed by 400 fig/day for the next two days; the patients were transferred to oral treatment at the same dose after the third day. Of the isolated pathogens, the staphylococcus species were sensitive to pefloxacin with MIC 0.12 to 0.5 mg/L, while the streptococci were resistant with MIC 16 to 32 mg/L. After 13 days treatment of 11 (73%) of the 15 episodes peritonitis was successful ( 55) .Treatment failed in three cases of peritonitis due to streptococcus and in one due to a Staph. epidermidis sensitive initiallyMIC 0.5 mg/L during therapy, the latter became resistant (MIC 8 mg/L).
The CAPD patients tolerated ciprofloxacin, ofloxa cin, a nd pefloxacin well; adverse reactions were un common, mild and reversible after drug withdrawal. The overall rate of adverse reactions was 4 to 8% and in only 1.0 to 2.6% of cases did treatment have to be discontinued (56) . The most common adverse reactions were gastrointestinal-anorexia, nausea, abdominal pain, vomiting or diarrhea; these were followed by central nervous system effects-dizziness, headache, and insomnia (53) . Some workers have reported cutaneous reactions such as rash, pruritus, and photosensitivity and also arthralgia and myalgia (57) .
Although no comparisons have been done with parenteral antibiotics with regard to side effects, one would expect more serious reactions with the parenteral regimens. On the other hand, the fluoroquino lones are better tolerated than the other oral antibiotics, such as semisynthetic penicillins, cotrimoxazole, or doxycycline (58) .
Recently, some have suggested that CAPD patients who are skin and nasal Staph. aureus carriers develop exit-site infections or peritonitis due to the same phage type of staphylococcus more frequently than do noncarrrers.
In future, oral fluoroquinolones are likely to be useful in prophylaxis against these current states. Thus, in 15 hemodialysed patients with nasal colonization by methicillin-resistant Staph. aureus oral ciprofloxacin at a dose of 750 mg twice a day for two to four weeks eradicated the carrier state in 73% of patients (59) . Furthermore, according to Smith et al., initially ciprofloxacin eradicated methicillin-resistant Staph. aureus from various skin areas or nose in 50% of patients whether treatment was for 5 or up to 14 days. When ciprofloxacin was combined with rifampicin in doses 750 mg and 300 mg twice a day, respectively, the eradication rate was 100% and the patients remained free of colonization at a one-month followup (60) . The superior results obtained with the ciprofloxacin/rifampicin combination suggest that this combination is synergistic in vivo against staphylococcus possibly because it achieves sufficiently high levels in tissues or secretions, it has excellent antistaphylococcal action, and it is able to kill intracellular organisms.
Ofloxacin given to nasal carriers in a of dose 400 to 800 mg a day for 10 to 14 days eradicated staphylococcus in 93 to 100% of patients. Three weeks after discontinuation of treatment, none of the patients had become recolonized (59) . However, we need more extensive clinical trials to confirm these initially encouraging results.
Vellend reported microbial resistance to fluoroquinolones (61) . In vitro studies show that serial exposure of bacteria to subinhibitory concentrations produced high levels of resistance to quinolones and a cross resistance among all the quinolones is not un common (62) . Although clinical resistance has been observed during therapy, this is small and occurs chiefly in selected populations such as the immuno compromised, those with cystic fibrosis, exacerbations of chronic infections and poor vascular supply (63) .
So f ar, we have no clinical studies in CAPD patients concerning the emergence of resistance after fluoroquinolone. When ciprofloxacin and pefloxacin were used to treat experimental Pseudamanas aeruginasa peritonitis, microbial resistance developed with low doses (ciprofloxacin 10 mg/kg and pefloxacin 25 mg/kg) in the presence of large numbers of bacteria (64) . However, the precise point at which resistance develops remains to be defined.
In conclusion, the fluoroquinolones offer a promis ing alternative to standard parenteral treatments in CAPD patients. Furthermore, their good oral bioavailability makes them attractive convenient for both patients and hospital staff. Their role in chemoprophylaxis remains to be documented and we must await future trials. As with all the new antimicrobial agents, we must use the fluoroquinolones with caution in clinical practice until we have more information and gain further experience.
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